Dow Down0.18% Nasdaq Up0.39%

Vertex Pharmaceuticals Incorporated (VRTX)

92.96 0.61(0.65%) Sep 2, 4:15PM EDT
|After Hours : 92.96 0.00 (0.00%) Sep 2, 4:24PM EDT
ProfileGet Profile for:
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
United States - Map
Phone: 617-341-6100

Index Membership:N/A
Full Time Employees:1,800

Business Summary 

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. It markets KALYDECO in the United States and European Union as a treatment for the patients with cystic fibrosis six years of age and older who have the G551D mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company also provides INCIVEK in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus infection, as well as markets telaprevir in other international markets. It also develops Ivacaftor in combination with CFTR corrector compounds, which is in Phase III development program; and evaluates VX-661, a second investigational CFTR corrector, in combination with ivacaftor, in Phase II clinical development. The company identifies and develops next-generation CFTR corrector compounds that evaluate in regimens combining ivacaftor with two CFTR corrector compounds. It is involved in various other research and early-stage development programs, including programs in the areas of oncology, multiple sclerosis, and other serious and rare diseases. Vertex Pharmaceuticals Incorporated has collaboration agreements with Janssen Pharmaceutica NV and Mitsubishi Tanabe Pharma Corporation. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Vertex Pharmaceuticals Incorporated

Corporate Governance 
Vertex Pharmaceuticals Incorporated’s ISS Governance QuickScore as of Sep 1, 2014 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 9.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Jeffrey M. Leiden M.D., Ph.D., 58
Chairman, Chief Exec. Officer and Pres
Dr. Joshua S. Boger Ph.D., 62
Founder, Exec. Director and Chairman of Science & Technology Committee
Mr. Ian F. Smith CPA, ACA, 48
Chief Financial Officer and Exec. VP
Dr. Peter R. Mueller Ph.D., 57
Chief Scientific Officer, Exec. VP of Global R&D and Member of The Scientific Advisory Board
Mr. Kenneth L. Horton , 47
Chief Legal Officer and Exec. VP
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders